Gopalsamy Srinivasa Nithin, Shah N Sarita, Marconi Vincent C, Armstrong Wendy S, Del Rio Carlos, Pennisi Eugene, Wortley Pascale, Colasanti Jonathan A
Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA.
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Open Forum Infect Dis. 2022 Jul 8;9(7):ofac338. doi: 10.1093/ofid/ofac338. eCollection 2022 Jul.
Persons with human immunodeficiency virus (PWH) may experience a cycle of engaging and disengaging in care referred to as "churn." While human immunodeficiency virus (HIV) churn is predicted to be more prevalent in the southern United States (US), it has not been well characterized in this region.
We conducted a retrospective cohort study involving PWH newly establishing care at a large urban clinic in Atlanta, Georgia, from 2012 to 2017, with follow-up data collected through 2019. The primary exposure was churn, defined as a ≥12-month gap between routine clinic visits or viral load (VL) measurements. We compared HIV metrics before and after churn and assessed the risk of future churn or loss to follow-up.
Of 1303 PWH newly establishing care, 81.7% were male and 84.9% were Black; 200 (15.3%) experienced churn in 3.3 years of median follow-up time. The transmissible viremia (TV) rate increased from 28.6% prechurn to 66.2% postchurn ( < .0001). The 122 PWH having TV on reengagement had delayed time to subsequent viral suppression (adjusted hazard ratio, 0.59 [95% confidence interval {CI}, .48-.73]), and PWH returning to care contributed disproportionately to the community viral load (CVL) (proportion of CVL/proportion of patients, 1.96). Churn was not associated with an increased risk of subsequent churn (adjusted odds ratio [aOR], 1.53 [95% CI, .79-2.97]) or loss to follow-up (aOR, 1.04 [95% CI, .60-1.79]).
The rate of churn in a southern US clinic was high, and those who experienced churn had increased TV at reentry and disproportionately contributed to the CVL and likely contributing to ongoing HIV transmission.
感染人类免疫缺陷病毒(HIV)的人(PWH)可能会经历一种参与和脱离治疗的循环,即“反复无常”。虽然预计美国南部地区HIV反复无常的情况更为普遍,但该地区尚未得到充分描述。
我们进行了一项回顾性队列研究,研究对象为2012年至2017年在佐治亚州亚特兰大一家大型城市诊所新接受治疗的PWH,并收集了截至2019年的随访数据。主要暴露因素是反复无常,定义为常规门诊就诊或病毒载量(VL)测量之间间隔≥12个月。我们比较了反复无常前后的HIV指标,并评估了未来反复无常或失访的风险。
在1303名新接受治疗的PWH中,81.7%为男性,84.9%为黑人;在中位随访时间3.3年中,200人(15.3%)出现反复无常。可传播病毒血症(TV)率从反复无常前的28.6%升至反复无常后的66.2%(P<0.0001)。重新参与治疗时出现TV的122名PWH后续病毒抑制时间延迟(调整后的风险比,0.59[95%置信区间{CI},0.48 - 0.73]),重新接受治疗的PWH对社区病毒载量(CVL)的贡献不成比例(CVL比例/患者比例,1.96)。反复无常与后续反复无常风险增加(调整后的优势比[aOR],1.53[95%CI,0.79 - 2.97])或失访风险增加(aOR,1.04[95%CI,0.60 - 1.79])无关。
美国南部一家诊所的反复无常率很高,经历反复无常的人重新参与治疗时TV增加,对CVL的贡献不成比例,可能导致HIV持续传播。